More News

01 Apr 2022 Fresenius Kabi buys a majority stake in mAbxience and acquires Ivenix to accelerate strategic growth in Biopharmaceuticals and MedTech
31 Mar 2022 Myeloid Therapeutics and Prime Medicine Enter Into Exclusive Option and Research Collaboration to Develop and Accelerate Next-Generation RNA-based Gene-Editing Technology, RetroT™
29 Mar 2022 Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets
23 Mar 2022 Jacobio Announces Annual Results of 2021, R&D Investment Increases 83%
22 Mar 2022 Spotlight Therapeutics Raises $36.5 Million Series B to Advance a Pipeline of Cell-Targeted In Vivo CRISPR Gene Editing Biologics
22 Mar 2022 Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations
21 Mar 2022 RNAGENE Signs a Collaborative Research Agreement with PharmAbcine to Develop Novel mRNA Therapeutics
21 Mar 2022 Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb
17 Mar 2022 Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals
16 Mar 2022 Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates
16 Mar 2022 AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19
12 Mar 2022 AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases
10 Mar 2022 Twist Bioscience and Kriya Sign Agreement to Discover Novel Antibodies for Applications in Oncology Using Gene Therapy
10 Mar 2022 Novo Nordisk expands research collaboration in novel delivery technologies for biologic medicines
09 Mar 2022 Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs
08 Mar 2022 Creyon Bio Launches to Engineer Safe, Effective Precision Medicines on Demand for All Patients
08 Mar 2022 NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
02 Mar 2022 Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates
02 Mar 2022 AstraZeneca and Neurimmune close exclusive global collaboration and licence agreement to develop and commercialise NI006
02 Mar 2022 AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
01 Mar 2022 Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies
01 Mar 2022 NextRNA Launches with $56 Million in Funding to Bring Transformative Non-coding RNA-directed Medicines to Patients
28 Feb 2022 Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
25 Feb 2022 Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb
23 Feb 2022 Code Biotherapeutics Announces Collaboration with Takeda to Use Proprietary 3DNA Genetic Medicine Delivery Platform to Design and Develop Gene Therapies for Rare Diseases

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up